Sulfated polysaccharides effectively inhibit SARS-CoV-2 in vitro

Paul S Kwon, Hanseul Oh, Seok-Joon Kwon, Weihua Jin, Fuming Zhang, Keith Fraser, Jung Joo Hong, Robert J Linhardt, Jonathan S Dordick, Paul S Kwon, Hanseul Oh, Seok-Joon Kwon, Weihua Jin, Fuming Zhang, Keith Fraser, Jung Joo Hong, Robert J Linhardt, Jonathan S Dordick

No abstract available

Keywords: Glycobiology; Mechanisms of disease.

Conflict of interest statement

Conflict of interestThe authors declare that they have no conflict of interest.

Figures

Fig. 1. Assessment of antiviral activities of…
Fig. 1. Assessment of antiviral activities of certain sulfated polysaccharides.
a Surface plasmon resonance (SPR) experiments were used to screen polysaccharides that outcompete immobilized heparin binding to SARS-CoV-2 S-protein. Data are presented as mean±s.d., n=3 biologically independent samples. A two-sided t-test was performed to test significance against the control (P1<0.0001, P2=0.0003, P3=0.0016, P4=0.0041). b Structural units comprising polysaccharides used for in vitro antiviral studies. c Focus reduction assay images of virus infection on treatment of indicated polysaccharides. At 48h after infection, Vero cells were fixed and probed with SARS-CoV-2 spike primary antibody (1:10000, Sino Bio Inc.) and HRP-conjugated goat rabbit (1:10000, Abcam) secondary antibody. d Vero cells were infected with SARS-CoV-2 at a MOI of 2.5×10−3 at different doses of each polysaccharide for 48h. The viral yield was quantified using a focus reduction assay. Cytotoxicity in Vero cells was measured using a WST-1 assay. The left and right y-axis of the graphs represent mean % inhibition of virus yield and cytotoxicity of the polysaccharides, respectively. Cytotoxicity experiments were performed in duplicate with n=3 biologically independent samples. Focus reduction assay experiments were performed in mean±s.d. (quadruplicate measurements) with n=3 biologically independent samples. e The RBD-ACE2-binding interface is stabilized by an extensive hydrogen bonding network involving sidechains of several residues on both RBD and ACE2. Polar sidechains of N487, Y489, Q493, Q498, and Y505 on the spike protein RBD along with other residues would be able to bind to heparin and inhibit RBD-ACE2 interaction. Heparin (here an octasaccharide) forms a hydrogen bond network with N448, N450, Q493, and N501 that aids in its occupancy of this binding regions and sterically restrict access to Q498, Y489, and Y505 necessary for ACE2 receptor binding.

References

    1. World Health Organization. Coronavirus disease (COVID-199) situation reports. WHO. (2020).
    1. Wu D, et al. Vaccines and therapies in development for SARS-CoV-2 infections. J. Clin. Med. 2020;9:E1885. doi: 10.3390/jcm9061885.
    1. Kim, S. Y. et al. Characterization of heparin and severe acute respiratory syndrome-related coronavirus 2 (SARS-CoV-2) spike glycoprotein binding interactions. Antiviral Res.181, 104873. 10.1016/j.antiviral.2020.104873 (2020).
    1. Matsuyama S, et al. Enhanced isolation of SARS-CoV-2 by TMPRSS2-expressing cells. Proc. Natl Acad. Sci. USA. 2020;117:7001–7003. doi: 10.1073/pnas.2002589117.
    1. Harcourt J, et al. Severe acute respiratory syndrome coronavirus 2 from patient with coronavirus disease, United States. Emerg. Infect. Dis. 2020;26:1266–1273. doi: 10.3201/eid2606.200516.
    1. Jin W, Wang J, Ren S, Song N, Zhang Q. Structural analysis of a heteropolysaccharide from Saccharina japonica by electrospray mass spectrometry in tandem with collision-induced dissociation tandem mass spectrometry (ESI-CID-MS/MS) Mar. Drugs. 2012;10:2138–2152. doi: 10.3390/md10102138.
    1. Cress BF, et al. Heavy heparin: a stable isotope-enriched, chemoenzymatically-synthesized, poly-component drug. Angew. Chem. Int. Ed. Engl. 2019;58:5962–5966. doi: 10.1002/anie.201900768.
    1. Lin YP, et al. Non-anticoagulant heparin as a pre-exposure prophylaxis prevents lyme disease infection. ACS Infect. Dis. 2020;6:503–514. doi: 10.1021/acsinfecdis.9b00425.
    1. Wang M, et al. Remdesivir and chloroquine effectively inhibit the recently emerged novel coronavirus (2019-nCoV) in vitro. Cell Res. 2020;30:269–271. doi: 10.1038/s41422-020-0282-0.
    1. Jeon S, et al. Identification of antiviral drug candidates against SARS-CoV-2 from FDA-approved drugs. Antimicrob. Agents Chemother. 2020;64:e00819–e00820. doi: 10.1128/AAC.00819-20.
    1. Mycroft-West, C. J. et al. Heparin inhibits cellular invasion by SARS-CoV-2: structural dependence of the interaction of the surface protein (spike) S1 receptor binding domain with heparin. BioRxiv10.1101/2020.04.28.066761 (2020).
    1. Nemanichvili N, et al. Fluorescent trimeric hemagglutinins reveal multivalent receptor binding properties. J. Mol. Biol. 2019;431:842–856. doi: 10.1016/j.jmb.2018.12.014.
    1. Shang J, et al. Structural basis of receptor recognition by SARS-CoV-2. Nature. 2020;581:221–224. doi: 10.1038/s41586-020-2179-y.
    1. Sungnak W, et al. SARS-CoV-2 entry factors are highly expressed in nasal epithelial cells together with innate immune genes. Nat. Med. 2020;26:681–687. doi: 10.1038/s41591-020-0868-6.
    1. Lamers MM, et al. SARS-CoV-2 productively infects human gut enterocytes. Science. 2020;369:50–54. doi: 10.1126/science.abc1669.
    1. Grein J, et al. Compassionate use of remdesivir for patients with severe Covid-19. N. Engl. J. Med. 2020;382:2327–2336. doi: 10.1056/NEJMoa2007016.
    1. Paranjpe I, et al. Association of treatment dose anticoagulation with in-hospital survival among hospitalized patients with COVID-19. J. Am. Coll. Cardiol. 2020;76:122–124. doi: 10.1016/j.jacc.2020.05.001.
    1. Chimenti L, et al. Nebulized heparin attenuates pulmonary coagulopathy and inflammation through alveolar macrophages in a rat model of acute lung injury. Thromb. Haemost. 2017;117:2125–2134. doi: 10.1160/TH17-05-0347.

Source: PubMed

Sponsorzy i współpracownicy

Warunki medyczne

Interwencje lekowe

3
Subskrybuj